Polymyositis Market Size Forecasted To Achieve 2.22 Billion By 2029 With Steady Growth

Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.

What Is the Polymyositis Market Size and Projected Growth Rate?
The market size of polymyositis has seen a considerable surge recently. Projections show that it will inflate from $1.65 billion in 2024 to $1.75 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 6.4%. This growth in the past period is due to factors like enhanced accessibility in emerging areas, an uptick in prednisone utilisation, an increased acceptance of methotrexate for symptom management, a surge in TNF inhibitors usage, and the heightened application of antibody testing.

The market for polymyositis is projected to experience substantial growth in the coming years, with predictions stating it will reach $2.23 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 6.2%. This anticipated growth during the forecast period can be linked to advancements in telemedicine, the increasing application of remote monitoring, an upward trend in the utilization of immunosuppressants, a surge in stem cell therapy applications, and enhanced use of biosimilars. Key trends expected to define this period include the introduction of artificial intelligence in the drug discovery process, progress in targeted therapies, creation of innovative immunomodulators, a surge in regenerative medicine research, and the incorporation of big data.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=22104

What Are the Major Segments in the Polymyositis Market?
The polymyositis market covered in this report is segmented -

1) By Type: Idiopathic Polymyositis, Dermatomyositis, Inclusion Body Myositis, Overlapping Myositis Syndromes
2) By Diagnosis: Physical Examination, Muscle Biopsy, Electromyography (EMG), Blood Tests, Magnetic Resonance Imaging (MRI)
3) By Treatment: Immunosuppressant, Immunoglobulins, Corticosteroids, Alkylating agents, Monoclonal Antibodies
4) By Distribution Channel: Offline, Online
5) By End User: Hospital pharmacy, Online pharmacy, Retail pharmacy

Subsegmentss:

1) By Idiopathic Polymyositis: Immune-Mediated Polymyositis, Virus-Associated Polymyositis
2) By Dermatomyositis: Classic Dermatomyositis, Amyopathic Dermatomyositis, Juvenile Dermatomyositis
3) By Inclusion Body Myositis: Sporadic Inclusion Body Myositis, Hereditary Inclusion Body Myopathy
4) By Overlapping Myositis Syndromes:Polymyositis with Systemic Lupus Erythematosus (SLE), Polymyositis with Rheumatoid Arthritis (RA), Polymyositis with Systemic Sclerosis, Polymyositis with Mixed Connective Tissue Disease (MCTD)

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=22104&type=smp

What Are The Driving Polymyositis Market Evolution?
The growth of the polymyositis market is expected to be fostered by the escalating prevalence of autoimmune diseases. These diseases occur when the body's immune system erroneously attacks its own healthy cells, tissues, or organs, causing inflammation and damage. Increase in autoimmune conditions is attributed to specific genetic variants that trigger an excessive immune response, causing the body to mistakenly harm its own tissues. This proneness to the condition, coupled with environmental factors like infections, stress, and lifestyle habits add to the growing incidence of autoimmune diseases. Knowledge about polymyositis has augmented the understanding of autoimmune conditions, as it demonstrates how goof-ups in the immune system can lead to muscle inflammation, thereby providing knowledge about possible treatments for related conditions. For instance, Versorgungsatlas.de, based in Germany, indicated that in 2022, out of 73,241,305 insured individuals, 6,304,340 were diagnosed with one or more autoimmune diseases which amounts to a rough prevalence rate of 8.61%. Thus, the rise in autoimmune disease instances is fuelling the polymyositis market. The polymyositis market is projected to further grow due to an uptick in demand for oral drugs. Oral medications, which are taken orally in forms like tablets, capsules, or liquids, and absorbed through the digestive tract, are preferred due to their benefits, such as convenience, non-intrusive administration, and preference by patients. Polymyositis is typically managed with oral medication that helps lower muscle inflammation, adjust the immune system, and boost muscle function, as a result, these drugs alleviate symptoms and hinder disease progression. An instance that can be cited here is from October 2022, when the Centers for Disease Control and Prevention, a US-based governmental organization, reported that prescriptions for oral antivirals shot up by 57%, surging from 643 per 100,000 people between April 24 and May 21, 2022, to 1,012 per 100,000 people between July 31 and August 28, 2022. Therefore, the pneumogastric market is driven by this heightened demand for oral medication.

Which Firms Dominate The Polymyositis Market Segments?
Major companies operating in the polymyositis market are Pfizer Inc., F. Hoffmann-La Roche AG, Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Merck & Co. Inc., C.H. Boehringer Sohn AG & Co. KG, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Fresenius SE & Co. KGaA, UCB S.A., Reliance Life Sciences Private Limited, ARUP Laboratories, Teva Pharmaceuticals USA Inc., Kezar Life Sciences Inc., Argenx SE, Mallinckrodt Pharmaceuticals plc, Mitsubishi Tanabe Pharma Corporation, ViiV Healthcare Limited

What Trends Are Expected to Dominate the Polymyositis Market in the Next 5 Years?
Large firms in the polymyositis market are concentrating their efforts on creating innovative treatments such as stem cell therapy to increase the effectiveness of treatment and slow down disease progression. The premise of stem cell therapy involves utilizing stem cells derived from the umbilical cord for regenerative purposes. The strong immunomodulatory and anti-inflammatory features of these stem cells make them a viable treatment option for autoimmune diseases like polymyositis. For example, in December 2024, the U.S. Food and Drug Administration (FDA) granted RESTEM, a US-based biotechnology company in its clinical stage, Orphan Drug Designation (ODD) for their stem cell plan using umbilical cord outer lining stem cells (ULSCs). The treatment method, which employs ULSCs to manage the immune system and reduce muscle inflammation, has shown encouraging safety and efficacy in its preliminary trials for treating both polymyositis and Dermatomyositis. Furthermore, it shows potential in reducing dependency on steroids.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/polymyositis-global-market-report

Which Is The Largest Region In The Polymyositis Market?
North America was the largest region in the polymyositis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the polymyositis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Polymyositis Market?
2. What is the CAGR expected in the Polymyositis Market?
3. What Are the Key Innovations Transforming the Polymyositis Industry?
4. Which Region Is Leading the Polymyositis Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.